I. Executive Summary Background The 5 years since the publication of the first International
Consensus Statement on Allergy and Rhinology: Rhinosinusitis (ICAR‐RS) has witnessed …

Background Chronic rhinosinusitis with nasal polyposis (CRSwNP) is an inflammatory
condition of the upper airways. Optimal management is unclear. Objective We compared the …

This systematic review evaluates the efficacy and safety of biologicals for chronic
rhinosinusitis with nasal polyps (CRSwNP) compared with the standard of care. PubMed …

Biologics for chronic rhinosinusitis - Chong, LY - 2021 | Cochrane Library Skip to Content
Cookies Our site uses cookies to improve your experience. You can find out more about our …

The aim of this study has been to evaluate the efficacy of the IL-5 receptor blocker
benralizumab on chronic rhinosinusitis with nasal polyposis (CRSwNP), associated with …

Biologic therapy is a new treatment option for patients with chronic rhinosinusitis with nasal
polyps (CRSwNP). Currently, the only biologic with Food and Drug Administration–approval …

Background The heterogeneity of existing studies, along with the fact that there are no
published head‐to‐head trials, are the main reasons for the lack of guidelines regarding the …

Allergic fungal rhinosinusitis (AFRS) is a highly resistant disease and is challenging to treat.
Patients with recurrent attacks of the disease despite surgical management can benefit from …

Objective To review the current literature regarding the role of biologics in the treatment of
chronic rhinosinusitis with nasal polyposis (CRSwNP). Data Sources PubMed/MEDLINE …

Background Biologic therapy targeting type 2 chronic rhinosinusitis with nasal polyps
(CRSwNP) has greatly improved disease control but nonresponders exist in a proportion of …